The Emerging Role of Digital Therapeutics in Medical, Surgical and Radiation Oncology SA–CME REVIEW from DTx. In the setting of a global pandemic, remote access became increasingly important, yet digital inclusion may be lacking and must be factored in when developing and incorporating DTx solutions since digital access can be consid- ered a new social determinant of health. 70,71 In this age of all things digital and data-driven, thoughtful management and oversight of data is critical to producing meaningful yet relevant results. One potential area to expand digital inclusion may be with the opportuni- ties within the decentralized clinical trial (DCT) landscape. 72 Since only 5% of eligible patients participate in clin- ical trials, there may be significant improvement with DCTs such that a wider range of patients can enroll sec- ondary to the reduced costs and com- mitments. Mitigation of economic, geographic, and job disparities may be possible with DCTs and DTx with ePROs may have a prominent role. With this system, it may be possible to recruit digitally from communities that have been historically marginal- ized from clinical trials. Current in- frastructure to foster the widespread adoption of DCTs is lacking but with the continued emerging spectrum of DTx, such support may soon arise. At one of the author’s institutions, incorporating DTx into the clinic work- flow required a few “readiness checks.” DTx utility is demographic dependent. Prior to an attempt at introducing DTx into the clinic, each institution’s pa- tient and staff constituency should be evaluated for digital literacy, DTx ac- ceptability, electronic medical record interoperability, and avenues for finan- cial support in the anticipated absence of insurance reimbursements. Conclusion DTx is a subdivision of digital health defined by evidence-based soſtware interventions to prevent, manage, or treat a medical disorder or disease. Although formal use of the term dates back to 2012, 2 only more recently have studies reported improved outcomes with the inte- gration of DTx into clinical practice. Given the potential for DTx to im- prove outcomes across the spectrum of cancer care, further data in the oncology setting is eagerly awaited. References 1) Gussoni G, Ravot E, Zecchina M, et al. Digital therapeutics in oncology: find- ings, barriers and prospects. A narrative review. Ann Res Oncol. 2022;02(01):55. doi:10.48286/aro.2022.39 2) Dang A, Arora D, Rane P. Role of digital therapeutics and the changing future of healthcare. J Family Med Prim Care. 2020;9(5):2207-2213. doi:10.4103/ jfmpc.jfmpc_105_20 3) US Food and Drug Administration. Digital Health Soſtware Precertification (Pre-Cert) Program. FDA. Published March 8, 2022. Accessed April 13, 2022. https://www.fda.gov/ medical-devices/digital-health-center-excel- lence/digital-health-soſtware-precertifica- tion-pre-cert-program 4) Patel NA, Butte AJ. Characteristics and challenges of the clinical pipeline of digital therapeutics. NPJ Digit Med. 2020;3(1):159. doi:10.1038/s41746-020-00370-8 5) Recchia G, Maria Capuano D, Mistri N, Verna R. Digital therapeutics–what they are, what they will be. Act Sci Medic. 2020;4(3):01- 09. doi:10.31080/ASMS.2020.04.0575 6) Sverdlov O, van Dam J, Hannesdottir K, Thornton-Wells T. Digital therapeutics: an integral component of digital innovation in drug development. Clin Pharmacol Ther. 2018;104(1):72-80. doi:10.1002/cpt.1036 7) Jaffee EM, Dang CV, Agus DB, et al. Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncol. 2017;18(11):e653-e706. doi:10.1016/ S1470-2045(17)30698-8 8) Kerr J, Anderson C, Lippman SM. Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence. Lancet Oncol. 2017;18(8):e457-e471. doi:10.1016/S1470-2045(17)30411-4 9) Sandman K, Vieweg DC, Forsythe A. PNS85 Economic evaluations of digital therapeutics (DTX) from a US perspective. Value Health. 2021;24:S188. doi:10.1016/j.jval.2021.04.939 10) Ritchie CS, Kvale E, Fisch MJ. Multimor- bidity: an issue of growing importance for oncologists. J Oncol Pract. 2011;7(6):371-374. doi:10.1200/JOP.2011.000460 11) Wolff JL, Starfield B, Anderson G. Prev- alence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162(20):2269-2276. doi:10.1001/archinte.162.20.2269 12) Birch K, Malecki MJ, MacEwan JP, Chung S. HSR22-131: Incremental health care costs of anxiety and depression among Medicare beneficiaries with cancer. J Nat Comp Cancer Net. 2022;20(3.5):HSR22-131. doi:10.6004/ jnccn.2021.7251 13) Williams GR, Deal AM, Lund JL, et al. Patient-reported comorbidity and surviv- al in older adults with cancer. Oncologist. 2018;23(4):433-439. doi:10.1634/theon- cologist.2017-0404 14) Aapro M, Bossi P, Dasari A, et al. Digital health for optimal supportive care in oncolo- gy: benefits, limits, and future perspectives. Support Care Cancer. 2020;28(10):4589-4612. doi:10.1007/s00520-020-05539-1 15) Thorvardardottir G, Gudmundsson H, Meszaros J, et al. A digital therapeutic intervention for breast cancer patients during active treatment: a feasibility study. Ann Oncol. 2022;33:224-231. doi:10.1016/ annonc/annonc895 16) Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symp- tom monitoring during routine cancer treatment. JAMA. 2017;318(2):197-198. doi:10.1001/jama.2017.7156 17) Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-re- ported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34(6):557-565. doi:10.1200/ JCO.2015.63.0830 18) Denis F, Yossi S, Septans AL, et al. Improving survival in patients treated for a lung cancer using self-evaluated symptoms reported through a web application. Am J Clin Oncol. 2017;40(5):464-469. doi:10.1097/ COC.0000000000000189 19) Cleeland CS, Wang XS, Shi Q, et al. Auto- mated symptom alerts reduce postoperative symptom severity aſter cancer surgery: a randomized controlled clinical trial. J Clin Oncol. 2011;29(8):994-1000. doi:10.1200/ JCO.2010.29.8315 20) Melstrom L, Rodin A, Rossi L, Fu P, Fong Y, Sun V. Patient generated health data and electronic health record integration in onco- logic surgery: a call for artificial intelligence and machine learning. J Surg Oncol. 2020;123. doi:10.1002/jso.26232 21) Basch E, Mody GN, Dueck AC. Electronic patient-reported outcomes as digital ther- apeutics to improve cancer outcomes. JCO Oncol Pract. Published online June 2, 2020. doi:10.1200/OP.20.00264 22) Barbera L, Sutradhar R, Seow H, et al. Impact of standardized Edmonton Symptom Assessment System use on emergency department visits and hospi- talization: results of a population-based retrospective matched cohort analysis. JCO Oncol Pract. 2020;16(9):e958-e965. doi:10.1200/JOP.19.00660 Applied Radiation Oncology 16 June 2022